title: Estimating the number needed to vaccinate to prevent diseases and death related to human papillomavirus infection.
abstract: BACKGROUND
  A vaccine against human papillomavirus (HPV) types 6, 11, 16 and 18 is now licensed for use in Canada and many other countries. We sought to estimate the number needed to vaccinate to prevent HPV-related diseases and death.
  
  
  METHODS
  A cohort model of the natural history of HPV infection was developed. Model simulations were based on 209 different parameter sets that reproduced Canadian HPV type-specific data for infection, cervical intraepithelial neoplasia, cervical cancer and genital warts. The number needed to vaccinate was calculated as the number of women who would need to be vaccinated to prevent an HPV-related event during their lifetime.
  
  
  RESULTS
  Among 12-year-old girls, we estimated that the number needed to vaccinate to prevent an episode of genital warts would be 8 (80% credibility interval [CrI] 5-15) and a case of cervical cancer 324 (80% CrI 195-757). These estimates were based on the assumption that the vaccine procures lifelong protection and that its efficacy is 95%. If vaccine protection is assumed to wane at 3% per year, the predicted number needed to vaccinate would increase to 14 (80% CrI 6-18) and 9080 (80% CrI 1040-does not prevent), respectively. The latter number would be greatly reduced with the addition of a booster dose, to 480 (80% CrI 254-1572).
  
  
  CONCLUSIONS
  Our model predictions suggest that vaccination with the currently available HPV vaccine may significantly reduce the incidence of genital warts, cervical intraepithelial neoplasia and cervical cancer. However, the benefits (particularly in terms of cervical cancer reduction) are highly dependent on the duration of vaccine protection, on which evidence is currently limited.
authors: Département de médecine sociale et préventive, Université Laval, Québec, Que. marc.brisson@uresp.ulaval.ca
authors: Marc
authors: M
authors: Brisson
authors: Nicolas
authors: N
authors: Van de Velde
authors: Philippe
authors: P
authors: De Wals
authors: Marie-Claude
authors: MC
authors: Boily
mesh_terms: D002170:Canada / Q000453:epidemiology; D002648:Child; D015331:Cohort Studies; D003198:Computer Simulation; D003218:Condylomata Acuminata / Q000453:epidemiology / Q000517:prevention & control* / Q000821:virology*; D005260:Female; D006801:Humans; D008962:Models, Theoretical; D030361:Papillomavirus Infections / Q000453:epidemiology / Q000517:prevention & control*; D053918:Papillomavirus Vaccines / Q000008:administration & dosage*; D018401:Sample Size; D035501:Uncertainty; D002583:Uterine Cervical Neoplasms / Q000453:epidemiology / Q000517:prevention & control* / Q000821:virology*; D002578:Uterine Cervical Dysplasia / Q000453:epidemiology / Q000517:prevention & control* / Q000821:virology*
chemical_list: D053918:Papillomavirus Vaccines
references: Vaccine. 2002 Jan 15;20(7-8):1113-25
references: 11803072
references: Sex Transm Infect. 2000 Jun;76(3):162-8
references: 10961190
references: N Engl J Med. 2003 Feb 6;348(6):518-27
references: 12571259
references: Clin Infect Dis. 2003 Jun 1;36(11):1397-403
references: 12766834
references: Br J Cancer. 2003 Jul 7;89(1):101-5
references: 12838308
references: J Natl Cancer Inst. 2004 Apr 21;96(8):604-15
references: 15100338
references: Vaccine. 2004 Jun 2;22(17-18):2192-8
references: 15149776
references: Virology. 2004 Jun 20;324(1):17-27
references: 15183049
references: J Clin Microbiol. 1995 Aug;33(8):2058-63
references: 7559948
references: Emerg Infect Dis. 2004 Nov;10(11):1915-23
references: 15550200
references: J Infect Dis. 2005 Mar 1;191(5):731-8
references: 15688287
references: Lancet Oncol. 2005 May;6(5):271-8
references: 15863374
references: Lancet. 2006 Apr 15;367(9518):1247-55
references: 16631880
references: Br J Cancer. 2006 Dec 4;95(11):1459-66
references: 17117182
references: Br J Cancer. 2007 Jan 15;96(1):143-50
references: 17146475
references: Br J Cancer. 2007 Feb 12;96(3):514-8
references: 17245341
references: Am J Epidemiol. 2007 Apr 1;165(7):762-75
references: 17276976
references: Emerg Infect Dis. 2007 Jan;13(1):28-41
references: 17370513
references: Vaccine. 2007 May 22;25(21):4324-33
references: 17445955
references: N Engl J Med. 2007 May 10;356(19):1915-27
references: 17494925
references: N Engl J Med. 2007 May 10;356(19):1928-43
references: 17494926
references: N Engl J Med. 2007 May 10;356(19):1991-3
references: 17494933
references: Vaccine. 2007 Jun 21;25(26):4931-9
references: 17499406
references: Vaccine. 2007 Jul 20;25(29):5433-40
references: 17560695
references: Clin Microbiol Rev. 2003 Jan;16(1):1-17
references: 12525422